Sandra A Springer1,2, Angela Di Paola3, Marwan M Azar1, Russell Barbour2, Breanne E Biondi1, Maureen Desabrais4, Thomas Lincoln4, Daniel J Skiest4, Frederick L Altice1,2,5,6. 1. AIDS Program, Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT. 2. Faculty of Medicine, Infectious Diseases, Center for Interdisciplinary Research on AIDS, Yale University School of Public Health, New Haven, CT. 3. Faculty of Medicine, Infectious Diseases, School of Public Health, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX. 4. Department of Medicine, Baystate Medical Center, Springfield, MA. 5. Division of Epidemiology of Microbial Diseases, Yale University School of Public Health, New Haven, CT. 6. Faculty of Medicine, Infectious Diseases, Centre of Excellence in Research in AIDS (CERiA), University of Malaya, Kuala Lumpur, Malaysia.
Abstract
OBJECTIVE: To determine whether extended-release naltrexone (XR-NTX) would improve or maintain viral suppression (VS) among prisoners or jail detainees with HIV and opioid use disorder (OUD) transitioning to the community. DESIGN: A 4-site, prospective randomized double-blind, placebo-controlled trial was conducted among prison and jail inmates with HIV and OUD transitioning to the community from September 2010 through March 2016. METHODS:Eligible participants (N = 93) were randomized 2:1 to receive 6 monthly injections of XR-NTX (n = 66) or placebo (n = 27) starting at release and observed for 6 months. The primary outcome was the proportion that maintained or improved VS (<50 copies/mL) from baseline to 6 months. RESULTS: Participants allocated to XR-NTX significantly improved to VS (<50 copies/mL) from baseline (37.9%) to 6 months (60.6%) (P = 0.002), whereas the placebo group did not (55.6% at baseline to 40.7% at 6 months P = 0.294). There was, however, no statistical significant difference in VS levels at 6 months between XR-NTX (60.6%) vs. placebo (40.7%) (P = 0.087). After controlling for other factors, only allocation to XR-NTX (adjusted odds ratio = 2.90; 95% confidence interval = 1.04 to 8.14, P = 0.043) was associated with the primary outcome. Trajectories in VS from baseline to 6 months differed significantly (P = 0.017) between treatment groups, and the differences in the discordant values were significantly different as well (P = 0.041): the XR-NTX group was more likely than the placebo group to improve VS (30.3% vs. 18.5%), maintain VS (30.3% vs. 27.3), and less likely to lose VS (7.6% vs. 33.3%) by 6 months. CONCLUSIONS:XR-NTX improves or maintains VS after release to the community for incarcerated people living with HIV with OUD.
RCT Entities:
OBJECTIVE: To determine whether extended-release naltrexone (XR-NTX) would improve or maintain viral suppression (VS) among prisoners or jail detainees with HIV and opioid use disorder (OUD) transitioning to the community. DESIGN: A 4-site, prospective randomized double-blind, placebo-controlled trial was conducted among prison and jail inmates with HIV and OUD transitioning to the community from September 2010 through March 2016. METHODS: Eligible participants (N = 93) were randomized 2:1 to receive 6 monthly injections of XR-NTX (n = 66) or placebo (n = 27) starting at release and observed for 6 months. The primary outcome was the proportion that maintained or improved VS (<50 copies/mL) from baseline to 6 months. RESULTS:Participants allocated to XR-NTX significantly improved to VS (<50 copies/mL) from baseline (37.9%) to 6 months (60.6%) (P = 0.002), whereas the placebo group did not (55.6% at baseline to 40.7% at 6 months P = 0.294). There was, however, no statistical significant difference in VS levels at 6 months between XR-NTX (60.6%) vs. placebo (40.7%) (P = 0.087). After controlling for other factors, only allocation to XR-NTX (adjusted odds ratio = 2.90; 95% confidence interval = 1.04 to 8.14, P = 0.043) was associated with the primary outcome. Trajectories in VS from baseline to 6 months differed significantly (P = 0.017) between treatment groups, and the differences in the discordant values were significantly different as well (P = 0.041): the XR-NTX group was more likely than the placebo group to improve VS (30.3% vs. 18.5%), maintain VS (30.3% vs. 27.3), and less likely to lose VS (7.6% vs. 33.3%) by 6 months. CONCLUSIONS:XR-NTX improves or maintains VS after release to the community for incarcerated people living with HIV with OUD.
Authors: Jaimie P Meyer; Javier Cepeda; Johnny Wu; Robert L Trestman; Frederick L Altice; Sandra A Springer Journal: JAMA Intern Med Date: 2014-05 Impact factor: 21.873
Authors: Anne Zinski; Andrew O Westfall; Lytt I Gardner; Thomas P Giordano; Tracey E Wilson; Mari-Lynn Drainoni; Jeanne C Keruly; Allan E Rodriguez; Faye Malitz; D Scott Batey; Michael J Mugavero Journal: Am J Public Health Date: 2015-08-13 Impact factor: 9.308
Authors: Stephanie S O'Malley; James C Garbutt; David R Gastfriend; Qunming Dong; Henry R Kranzler Journal: J Clin Psychopharmacol Date: 2007-10 Impact factor: 3.153
Authors: Daniel Wolfe; M Patrizia Carrieri; Nabarun Dasgupta; Alex Wodak; Robert Newman; R Douglas Bruce Journal: Lancet Date: 2011-04-30 Impact factor: 79.321
Authors: Panagiotis Vagenas; Angela Di Paola; Maua Herme; Thomas Lincoln; Daniel J Skiest; Frederick L Altice; Sandra A Springer Journal: J Subst Abuse Treat Date: 2014-03-12
Authors: Evgeny Krupitsky; Edward V Nunes; Walter Ling; Ari Illeperuma; David R Gastfriend; Bernard L Silverman Journal: Lancet Date: 2011-04-30 Impact factor: 79.321
Authors: Angela Di Paola; Thomas Lincoln; Daniel J Skiest; Maureen Desabrais; Frederick L Altice; Sandra A Springer Journal: Contemp Clin Trials Date: 2014-09-18 Impact factor: 2.226
Authors: Elizabeth L C Merrall; Azar Kariminia; Ingrid A Binswanger; Michael S Hobbs; Michael Farrell; John Marsden; Sharon J Hutchinson; Sheila M Bird Journal: Addiction Date: 2010-06-23 Impact factor: 6.526
Authors: Robin M Nance; Maria Esther Perez Trejo; Bridget M Whitney; Joseph A C Delaney; Fredrick L Altice; Curt G Beckwith; Geetanjali Chander; Redonna Chandler; Katerina Christopoulous; Chinazo Cunningham; William E Cunningham; Carlos Del Rio; Dennis Donovan; Joseph J Eron; Rob J Fredericksen; Shoshana Kahana; Mari M Kitahata; Richard Kronmal; Irene Kuo; Ann Kurth; W Chris Mathews; Kenneth H Mayer; Richard D Moore; Michael J Mugavero; Lawrence J Ouellet; Vu M Quan; Michael S Saag; Jane M Simoni; Sandra Springer; Lauren Strand; Faye Taxman; Jeremy D Young; Heidi M Crane Journal: Clin Infect Dis Date: 2020-02-14 Impact factor: 9.079
Authors: Sandra A Springer; Angela Di Paola; Russell Barbour; Marwan M Azar; Frederick L Altice Journal: J Acquir Immune Defic Syndr Date: 2018-09-01 Impact factor: 3.731
Authors: Evgeny Krupitsky; Elena Blokhina; Edwin Zvartau; Elena Verbitskaya; Dmitri Lioznov; Tatiana Yaroslavtseva; Vladimir Palatkin; Marina Vetrova; Natalia Bushara; Andrei Burakov; Dmitri Masalov; Olga Mamontova; Daniel Langleben; Sabrina Poole; Robert Gross; George Woody Journal: Lancet HIV Date: 2019-03-14 Impact factor: 12.767
Authors: Dharushana Muthulingam; Joshua Bia; Lynn M Madden; Scott O Farnum; Declan T Barry; Frederick L Altice Journal: J Subst Abuse Treat Date: 2019-01-26
Authors: Benjamin J Oldfield; Kathleen A McGinnis; E Jennifer Edelman; Emily C Williams; Adam J Gordon; Kathleen Akgün; Stephen Crystal; Lynn E Fiellin; Julie R Gaither; Joseph L Goulet; P Todd Korthuis; Brandon D L Marshall; Amy C Justice; Kendall Bryant; David A Fiellin; Kevin L Kraemer Journal: J Subst Abuse Treat Date: 2019-11-06